While the tumor antigen presentation was shown to be improved by immunogenic tumor cell death (ICD) inducers (mainly chemotherapeutic agents), the sustained CD8 T-cell activity can be triggered by immune checkpoint blockers (ICBs: anti-PD-1/PD-L1 and anti-CTLA-4 Ab). This evidence concerns the gene CD8A and neoplasm.